Genotyping made easy: ZipArray

Achieving the sensitivity of digital PCR by combining barcoded probes with the multiplex and friendly interface of an on-chip array

RoseBio provides a cost-effective alternative for targeted genotyping when wide genome methods are  impractical or unnecessary. Our arrays offer ready-to-use solutions for known targets, such as cancer mutations and drug resistance or susceptibility, and are easily customizable for novel targets, empowering precision medicine and pharmacogenomic translational research. ZipArray can implement novel, relevant, and actionable targets, including miRNAs, insertions, deletions, methylated sequences.

Technology

ZipArray is a universal DNA-encoded Array for ultrasensitive and rapid detection of structural variants and point mutations. It can rapidly incorporate any gene, mutation or indication of interest, with a workflow that is  plugged in existing lab instrumentation, such as  a workstation or a fluorescence scanner, and  relying on a standard sample preparation. It is easy-to-use and does not require specialized operators, while reducing both hands-on time, and time to result.

ZipArray Platform

A microarray-based assay  can distinguish known variants (i.e., viral variants or cancer mutations) present in clinical samples (tissues or biofluids) by simultaneously detecting a large number of mutations (10s or 100s) and wild-type.

After the nucleic acid extraction, target amplicons are amplified via PCR  and hybridized in solution with specific dual-domain oligonucleotide reporters. Each reporter has a discrimination domain complementary to the target gene sequence that form hybrids in solution with the amplified and fluorescent labeled fragments, that are finally directed by the second “barcode” domain at specific locations on specific probe -coated silicon chips. The array format is modular, flexible and easily customisable. The tunable and configurable design and rapid prototyping is enabled by in silico probe design that predicts optimal DNA/DNA interactions (probe-target). Our current format of 16-well slide, and 30 mutations per well, allows the analysis of 480 mutations in 32 multiplex  PCR reactions  The whole flow takes 2.5 hours and can be completely automated within a bench work station, with AI-aided interpretation of the results.

logo RoseBio white

ONCO ZipArray: Solid Tumor Mutational Profliing Array

All-in-one and ready to use kit for rapid and sensitive microarray based simultaneous detection of  actionable mutations in colorectal and lung cancer. The intended use covers both tissue and liquid biopsy. The first version of the assay covers mutations in KRAS, NRAS, EGFR, BRAF, MET and ALK genes, driving the response to targeted cancer drugs approved and or reccomended for use in the US and EU. The molecular oncology is agnostic to tumor site, but dependent on tumor molecular profile. We are updating the design of the ONCO ZipArray according to the evolution of clinical and regulatory science, as well as a portfolio of approved drugs and drug combinations for specific indications. 

RES4T ZipArray: Resistance profiling for precise Tuberculosis treatment

Second-in-line indication for development and validation of RoseBio diagnostic products implementing ZipArray platform is rapid and accurate detection of mutations leading to M. tuberculosis drug resistance. First version of RES4T ZipArray covers the panel of mutations known to be responsible for resistance to antibiotics used in the first line of treatment, including rifampicin, isoniazid, ethambutol, fluoroquinolones and streptomycin.

logo Rosebio
logo RoseBio white

ZipArray pipeline: towards high value, high volume diagnostics, and affordable pharmacogenomic and pharmacogenetics testing

We leverage the flexibility of ZipArray technology to rapidly evolve our pipeline according to pressing need to optimise treatments throughout the patient journey. Our platform is configurable by design, including in silico probes prediction and synthesis, the modular chip format and universal surface chemistry that pairs the feasibility of in-solution amplification and hybridisation, with high multiplex of on-chip mutation identification. We are designing and validating our first tests with intention to cover solid tumor profiling on tissue and liquid biopsy samples, and bridge the clinical research and identification of actionable genomic traits by omics approaches, into individualised therapy in cancer, and beyond. This includes transformation of advances in pharmacogenetics and pharmacogenomics to routine patient profiling unveiling the interindividual differences in drug responses in different diseases, to start with cancer and tuberculosis. We are constantly driven by updates released from regulatory agencies and clinical guidelines, and work with out partners to provide customized solutions.

The Power of Diversity

Problem inspired, Technology driven, we deliver the Healthcare Innovation that works